The NHS is paying for thousands of patients with multiple sclerosis to receive drugs that monitoring data suggest are not effective. James Raftery examines what went wrong with the access scheme that facilitated their use
No takes yet. Share an insight, caveat, or question.
James Raftery (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: